Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Diabetic Macular Edema Clinical Trial

Official title:

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants With Diabetic Macular Edema (DME)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05712720
• Other study ID #: RZ402-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 6, 2023
• Est. completion date: May 2024

Study information

• Verified date: December 2023
• Source: Rezolute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.

Description:

Diabetic macular edema (DME) is a common retinal microvascular complication in diabetic patients that can lead to progressive loss of visual acuity and ultimately to complete vision loss. DME is the main cause of vision loss in patients with Type 2 diabetes. There is a significant unmet medical need to develop better therapies of DME and diabetic retinopathy (DR). RZ402 is a potent and selective plasma kallikrein inhibitor (PKI), which is being developed as an oral therapy for the chronic treatment of DME and DR. This is a Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants with Diabetic Macular Edema (DME). A screening period of up to 4 weeks will evaluate eligibility. Once enrolled, patients will be randomized with a 1:1:1:1 ratio to receive RZ402 or placebo for up to 12 weeks. After completing dosing, the patient will enter into a 4 week follow up period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: May 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

General Inclusion Criteria:

1. Confirmed diabetes mellitus Type 1 or Type 2

2. Stable glycemic control

Study Eye Inclusion Criteria:

3. Mild to moderate non-proliferative diabetic retinopathy (NPDR) with retinal thickening due to CI-DME as determined by the Investigator.

4. Spectral Domain Optical Coherence Tomography (SD-OCT) foveal CST at screening measuring =320 µm (or corresponding values)

5. Best Corrected Visual Acuity ETDRS letter score at 4 meters of =78 letters at screening.

6. Media clarity, pupillary dilation, and participant cooperation sufficient for adequate clinical evaluations, OCT images and fundus photographs, at screening.

Fellow Eye Inclusion Criteria:

7. Best Corrected Visual Acuity ETDRS letter score at 4 meters of =5 letters at screening. Exclusion Criteria:

Study Eye Exclusion Criteria:

8. Received more than 3 anti-VEGF injections (including Avastin) and/or received a recent anti-VEGF injection within 8 weeks of Randomization.

9. Any history of retinal surgery or other surgical intervention for DME.

10. Intraocular surgery (including cataract surgery), within 12 weeks prior to Randomization, or anticipated need for ocular surgery during the study period.

11. History of trabeculectomy or other filtration surgery (prior laser trabeculoplasty and placement of iStent®1 in conjunction with cataract surgery is permitted if the procedure took place =12 weeks prior to Randomization).

12. Autoimmune idiopathic inflammatory eye disease such as anterior uveitis, or participants with history or signs of chronic inflammation.

13. Full thickness macular hole or retinal detachment.

14. Panretinal, macular focal, or grid laser photocoagulation within 16 weeks of Randomization or anticipated need for the use of laser photocoagulation during the study period.

15. Uncontrolled glaucoma, at screening, defined as IOP =25 mmHg.

16. The use of corticosteroids as follows:

1. Topical corticosteroids within 12 weeks prior to Randomization and throughout the remainder of the study.

2. Use of intraocular or sub-Tenon's steroids within 2 years of Randomization in phakic eyes or 9 months of Randomization in pseudophakic eyes, and throughout the remainder of the study.

Fellow Eye Exclusion Criteria:

17. Intraocular or sub-Tenon's steroid injection within 6 months of Randomization and throughout the remainder or the study.

General Exclusion:

18. Use of the following medications or substances within the specified timeframes below and throughout the remainder of the study. a. Within 16 weeks of Randomization: i. Systemic anti-VEGF or pro-VEGF treatments ii. Systemic, approved, or off-label drugs or devices used to treat DME iii. Participated in an investigational drug or device study within 16 weeks or 5 half-lives (whichever is longer) of Randomization, including systemic or ocular studies iv. Initiation of drugs or substances known to improve or worsen macular edema e.g., Latanoprost or phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil or others in PDE-5 class), but participants may remain on these drugs if they were initiated >16 weeks prior to Randomization. b. Within 12 weeks of Randomization: i. Use of tobacco- or nicotine- containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, vaping). c. Within 4 weeks of Randomization: i. Anti-coagulants, except for aspirin =325 mg/day and/or clopidogrel =75 mg/day (or equivalent drug class) ii. Total daily doses of Metformin >1000 mg iii. Total daily doses of niacin (Vitamin B3) >1.5 g/day iv. Use of systemic steroids at supraphysiologic doses (e.g., prednisone equivalent of 5 mg/day or hydrocortisone equivalent of 20 mg/day). v. Drugs that may affect the retina or optic nerve such as quinolones, thioridazine, deferoxamine, ethambutol, vigabatrin, and pentosan.

19. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST), or alkaline phosphatase (ALP) =2X upper limit of normal (ULN), total bilirubin =1.5X ULN, or gamma-glutamyl transferase (GGT) =3X ULN as per the central laboratory.

20. Estimated glomerular filtration rate (eGFR) at =45 mL/min and/or history of persistent micro or macro albuminuria.

21. History of current or prior (within 1 year of Randomization) any significant illness, or any medical history

22. History of bariatric surgery or other surgical or medical history

23. History of current or prior (within 1 year of Randomization) abnormal, clinically significant ECG including inadequately controlled hypertension

24. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding.

25. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury

26. Known history of human immune-deficiency virus (HIV), hepatitis C, or hepatitis B infection.

27. Malignancies within 3 years prior to Randomization

28. Donated more than 500 mL of blood or significant blood loss within 60 days before Randomization.

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Drug:
• Experimental: Group 1
RZ402 50 mg oral tablet, once daily for 3 months
• Experimental: Group 2
RZ402 200mg oral tablet, once daily for 3 months
• Experimental: Group 3
RZ402 400mg oral tablet, once daily for 3 months

Other:
• Placebo: Group 4
Placebo, once daily for 3 months

Locations

Country	Name	City	State
United States	Rezolute Investigative Site, Augusta, Georgia	Augusta	Georgia
United States	Rezolute Investigative Site, Austin, TX	Austin	Texas
United States	Rezolute Investigative Site, Bakersfield, California	Bakersfield	California
United States	Rezolute Investigative Site, Beverly Hills, California	Beverly Hills	California
United States	Rezolute Investigative Site, Bloomfield, New Jersey	Bloomfield	New Jersey
United States	Rezolute Investigative Site, Coral Springs, Florida	Coral Springs	Florida
United States	Rezolute Investigative Site, Deerfield Beach, Florida	Deerfield Beach	Florida
United States	Rezolute Investigative Site, Fort Lauderdale, Florida	Fort Lauderdale	Florida
United States	Rezolute Investigative Site, Fullerton, California	Fullerton	California
United States	Rezolute Investigative Site, Great Neck, New York	Great Neck	New York
United States	Rezolute Investigative Site, Ladson, South Carolina	Ladson	South Carolina
United States	Rezolute Investigative Site, Lenexa, Kansas	Lenexa	Kansas
United States	Rezolute Investigative Site, Lynchburg, Virginia	Lynchburg	Virginia
United States	Rezolute Investigative Site, McAllen, Texas	McAllen	Texas
United States	Rezolute Investigative Site, Modesto, California	Modesto	California
United States	Rezolute Investigative Site, New York, New York	New York	New York
United States	Rezolute Investigative Site, Oak Forest, Illinois	Oak Forest	Illinois
United States	Rezolute Investigative Site, Orlando, Florida	Orlando	Florida
United States	Rezolute Investigative Site, Phoenix, Arizona	Phoenix	Arizona
United States	Rezolute Investigative Site, Plano, Texas	Plano	Texas
United States	Rezolute Investigative Site, Reno, Nevada	Reno	Nevada
United States	Rezolute Investigative Site, Royal Oak, Michigan	Royal Oak	Michigan
United States	Rezolute Investigative Site, Saint Louis, Missouri	Saint Louis	Missouri
United States	Rezolute Investigative Site, San Antonio, Texas	San Antonio	Texas
United States	Rezolute Investigative Site, Springfield, Illinois	Springfield	Illinois
United States	Rezolute Investigative Site, Springfield, Oregon	Springfield	Oregon
United States	Rezolute Investigative Site, Willow Park, Texas	Willow Park	Texas
United States	Rezolute Investigative Site, Winter Haven, Florida	Winter Haven	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Rezolute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Events	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	16 weeks
Primary	Change in Central Subfield Thickness	Change from baseline in Central Subfield Thickness (CST), as measured by Spectral Domain Ocular Coherence Tomography (SD-OCT), compared to placebo.	12 weeks
Secondary	Change in BCVA	Change from baseline in Best Corrected Visual Acuity (BCVA) in the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, compared to placebo.	12 weeks
Secondary	Change from baseline in Diabetic Retinopathy Severity Score (DRSS), compared to placebo.	DRSS is scored on a range from 10 to 90 and where higher scores indicate a worse outcome.	12 weeks
Secondary	Repeat-dose Cmax of RZ402	Repeat-dose Cmax of RZ402	16 weeks
Secondary	Repeat-dose T1/2 of RZ402	Repeat-dose T1/2 of RZ402	16 weeks
Secondary	Repeat-dose AUC of RZ402	Repeat-dose AUC of RZ402	16 weeks